At closing price, Neogen#39;s market capitalisation stood at 614.98 crore

Thanks to the heavy buying, the stock was locked at 5 percent upper circuit

The issue price is fixed at higher end of price band of Rs 212-215 per share.

The reserved portion for qualified institutional buyers has seen subscription of 30.49 times and non-institutional investors 113.88 times while retail category oversubscribed 16.06 times so far.

The reserved portion for qualified institutional buyers was subscribed 95 percent and for non-institutional investors was 1.12 times while retail individual investors#39; category has seen subscription of 3.15 times.

Mehta Equities has come out with its report on Neogen Chemicals. The research firm has recommended to "Subscribe#39;#39; the IPO in its research report as on April 25, 2019

Anand Rathi said higher multiple is justified given the company’s ability to grow profitably and command better return ratios. Hence it recommended subscribing the issue

Neogen Chemicals (NCL) is manufacturers of bromine-based, and lithium-based, specialty chemicals

Choice Broking has come out with its report on Neogen Chemicals. The research firm has recommended to "Avoid#39;#39; the IPO in its research report as on April 22, 2019

Choice Broking has come out with its report on Neogen Chemicals. The research firm has recommended to "Avoid#39;#39; the IPO in its research report as on April 22, 2019

The Rs 1,345-crore public issue saw a massive subscription of 51.96 times during April 5-9, 2019

Metropolis Healthcare#39;s market valuation was at Rs 4,814.90 crore on the BSE

The stock opened with a 9 percent premium over its issue price of Rs 880 while on the National Stock Exchange it opened at Rs 958.